4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of$ 0.88. This compares to a loss of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.36%. A quarter ago, it was expected that this company would post a loss of$ 0.84 per share when it actually produced a loss of $0.86, delivering a surprise of -2.38%.Over the last four quarters, the c ...